JULIE: Hey, Laura
However, the absence of hepatic decompensation or overt hepatotoxicity in the ESSENCE trial is reassuring and supports the use of semaglutide in patients with F2-F3 fibrosis, with appropriate monitoring
Genitourinary Common (1% to 10%): Urinary tract infection, urolithiasis Postmarketing reports : Urolithiasis Hepatic Common (1% to 10%): Cholelithiasis, cholecystitis Uncommon (0.1% to 1%): Increased bilirubin Postmarketing reports : Cholecystitis, cholelithiasis requiring cholecystectomy Hypersensitivity Uncommon (0.1% to 1%): Hypersensitivity Rare (0.01% to 0.1%): Anaphylactic reaction Frequency not reported : Allergic reactions Postmarketing reports : Hypersensitivity, anaphylaxis Hypersensitivity included related adverse events such as rash and urticaria
But both alcohol and GLP-1s have been linked to pancreatitis, so its important to be mindful especially if you have other risk factors
Because semaglutide is no longer on the FDA Drug Shortages List, most compounding permissions have ended
They can also be avoided or minimized by ramping up dosage more slowly from the lowest starter dose of Ozempic to the higher dose thats typically used for ongoing treatment, Kushner says
